SD Biosensor

SD Biosensor Financial Leverage

The Financial Leverage (Equity Multiplier) of SD Biosensor (137310.KS) as of Oct 21, 2026 is 1.39. In the previous year, Financial Leverage (Equity Multiplier) was 1.33 — a change of 4.64% (higher).

Financial Leverage

1.39

YoY

4.64%

Last updated:

Financial Leverage (Equity Multiplier) of SD Biosensor is 2025 1.39 . Financial Leverage (Equity Multiplier) of SD Biosensor was 2024 1.33 . It decreases by 4.64% higher compared to the previous year.

The SD Biosensor Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.27 KRW
Jan 1, 2020
1.95 KRW
Jan 1, 2021
1.37 KRW
Jan 1, 2022
1.11 KRW
Jan 1, 2023
1.34 KRW
Jan 1, 2024
1.33 KRW
Jan 1, 2025
1.39 KRW
The SD Biosensor Financial Leverage history
YEARFinancial LeverageYoY
1.39+4.64%
1.33-0.87%
1.34+21.12%
1.11-19.24%
1.37-29.79%
1.95+53.59%
1.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SD Biosensor Stock analysis

What does SD Biosensor do? SD Biosensor Inc generates revenue through the development and manufacturing of cholesterol and blood glucose testing equipment. The company sells rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, and enzyme immunological reaction diagnosis products. These products are distributed domestically and internationally, targeting healthcare providers and consumers in the immunochemical, molecular, and point-of-care diagnosis sectors. The firm focuses on self blood glucose measurement and other diagnostic solutions for medical use. The company's product portfolio includes POCTs, which are used for point-of-care testing in medical settings. SD Biosensor Inc's offerings serve both the domestic market and overseas markets, with a strong emphasis on diagnostic equipment for healthcare applications. Their business model relies on the sale of these specialized medical devices to hospitals, clinics, and individual consumers seeking home health monitoring solutions. Revenue streams are derived from the research, development, and sale of diagnostic products, including immunochemical and molecular diagnosis tools. The firm's products are designed for use in clinical and self-testing environments, supporting both professional healthcare services and personal health management. SD Biosensor Inc's market segments include healthcare institutions and end-users requiring diagnostic testing for cholesterol, blood glucose, and other medical conditions. SD Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SD Biosensor stock

Financial Leverage (Equity Multiplier) of SD Biosensor is 1.39 in 2025.

Financial Leverage (Equity Multiplier) of SD Biosensor changed from 1.33 to 1.39, representing a 4.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) SD Biosensor since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s SD Biosensor with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SD Biosensor

All Key Metrics — SD Biosensor